Know Cancer

or
forgot password
  • cancer clinical trials in kansas city, KS

  • O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Brain and Central Nervous System Tumors
    S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Lymphoma
    Eflornithine in Treating Patients With Bladder Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Bladder Cancer
    S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Bladder Cancer
    S9804: Vinorelbine in Treating Patients With Stage IV Melanoma
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Melanoma (Skin)
    Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Graft Versus Host Disease, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
    Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Breast Cancer
    S9902 Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Head and Neck Cancer
    S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Melanoma (Skin), Metastatic Cancer
    Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Cardiac Toxicity, Sarcoma
    S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Lung Cancer
    S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Leukemia
    Combination Chemotherapy in Treating Children or Adolescents With Newly Diagnosed Stage III or Stage IV Lymphoblastic Lymphoma
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Lymphoma
    Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Cardiac Toxicity, Lymphoma
    Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Leukemia
    Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Leukemia
    S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Gastrointestinal Stromal Tumor
    S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Multiple Myeloma
    Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Leukemia, Lymphoma
    S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Leukemia
    S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Head and Neck Cancer
    S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Lung Cancer
    Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Lymphoma
    Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Cancer-related Problem/Condition, Head and Neck Cancer, Pain
    Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Leukemia
    Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Ovarian Cancer, Primary Peritoneal Cavity Cancer
    S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Esophageal Cancer, Gastric Cancer
    S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
    S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Lung Cancer
    S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
    Kansas Cancer Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7357
    Breast Cancer
    BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Prostate Cancer
    S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Breast Cancer
    S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Leukemia, Myelodysplastic Syndromes
    Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Kidney Cancer
    BMS-247550 in Treating Patients With Advanced Pancreatic Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Pancreatic Cancer
    Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Ovarian Cancer
    S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center

    Trial Locations
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Veterans Affairs Medical Center - Kansas City
    Malignant Neoplasms of Eye, Brain and Other Parts of Central Nervous System
    Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
    Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Leukemia, Lymphoma
    Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
    Tipifarnib in Treating Young Patients With Refractory Leukemia
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Leukemia
    S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
    Surgery Versus Internal Radiation in Treating Patients With Stage II Prostate Cancer
    Kansas Cancer Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7357
    Prostate Cancer
    Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Colorectal Cancer
    S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Leukemia
    Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Lymphoma
    S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Lung Cancer
    Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Pancreatic Cancer
    Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Melanoma (Skin)
    Effects of Ginseng and Ginkgo on Drug Disposition in Man
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Healthy
    S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Lung Cancer
    Radiosurgery With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Metastatic Cancer
    S9832: Effectiveness of Telephone Counseling By Breast Cancer Survivors on the Well-Being of Women With Recurrent Breast Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
    S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery
    Kansas Cancer Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7357
    Lung Cancer
    Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Esophageal Cancer, Gastric Cancer
    Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Breast Cancer
    S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Extrahepatic Bile Duct Cancer, Gallbladder Cancer
    Arsenic Trioxide in Treating Men With Germ Cell Cancer
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
    OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Pancreatic Cancer
    BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer